Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 69 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NUfBSZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnewNk42KM7:TR?= NHXacncyNTRiZB?= M{TafGROW09? NWPpcIE3\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? M3Lr[lI2PDlyM{iz
H1703 NFnOZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\vNk42KM7:TR?= MmKzNU01KGR? MljlSG1UVw>? NWT6NFVJ\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? MontNlU1QTB|OEO=
HUVECs MnH2R5l1d3SxeHnjbZR6KEG|c3H5 Mnz3NVAxKG6P NG\5V|UzPCCq NYfRPGtG[XS2ZX71ZZRmeyC2aHWgZYJzd2ejdHn2[UBm\m[nY4TzJI9nKGOjbInjc5NqdiCxbjDWVmkucW6mdXPl[EBkgXSxdH;4bYNqfHl? MV2yOVQ2ODF6Nh?=
APRE-19 NU[1PHU5SXCxcITvd4l{KEG|c3H5 MX61JO69VQ>? NVXoWlJ5OjRiaB?= NV3lW4M3[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= NUjab403OjV|Mkm2NVc>
MDA-MB-231 NYrUOY9CSXCxcITvd4l{KEG|c3H5 NFHCNlQyyqEQvF5CpC=> M2j2WVQ5KGh? MV7EUXNQ MYrk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= MlvlNlU{ODB7M{K=
MCF7 MkT0SpVv[3Srb36gRZN{[Xl? MknPNVAxKG6P MoDqNlQhcA>? MUflcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> NXLscZJROjVzN{K1OVc>
HT-29  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RNU42yqEEtV2= NXm3coZxQTZiaB?= NXjqZ3My\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> M2THbFI2ODF{MUKz
MO59K  MUPDfZRwfG:6aXPpeJkhSXO|YYm= MUO1xsDPxE1? NXjhSYdzPyCm MYrEUXNQ Mo\3[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M1nWelI1QTV|NU[x
MO59J MkmxR5l1d3SxeHnjbZR6KEG|c3H5 MlnCOeKh|ryP Mki5O{Bl MWDEUXNQ MVXlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MoHiNlQ6PTN3NkG=
MO59K  M163ZmFxd3C2b4Ppd{BCe3OjeR?= Mn7vNVAh|ryP NXHNXZVxOjRiaB?= NEjZUIpFVVOR M{njS4lv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NFjafZUzPDl3M{W2NS=>
MO59J NHr3Z5ZCeG:ydH;zbZMhSXO|YYm= MonZNVAh|ryP NEX3fo8zPCCq NHL1N4NFVVOR NInJXm5qdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NVnu[3R{OjR7NUO1OlE>
HepG2 NUfkT4pZTnWwY4Tpc44hSXO|YYm= NF[zbVIyODBibl2= MXywMlUhcA>? MnjjSG1UVw>? MlTiZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MV:yOFg3OzN3MB?=
A549  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rwe|MhyrWPwrC= NYjGcYpHOiCq M{jJd5N2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? MUKyOFg1Pzh4Mx?=
A549  Mn;kSpVv[3Srb36gRZN{[Xl? NUew[GszOTEEoN88ceKh NGHQNHoyPiCq NITS[VBFVVOR NInxZ4lud2S3bHH0[ZMhfGinIFnBWkBz\XCuaXPheIlwdiCjbnSgZ4F2e2W|IILleIVvfGmxbjDv[kBPWCCrbjD0bIUhdnWlbHX1d{4> NXzHdJd6OjR6MEKxNVE>
SK-N-LO MWXGeY5kfGmxbjDBd5NigQ>? MnTXNVAxKG6P NHnKNZcxNjViaB?= MXXk[YNz\WG|ZYOgeIhmKHO2aX31cIFvfCCnZn\lZ5R{KG:oIH3vdpBpcW6nIH;uJGFsfCCyaH;zdIhwenmuYYTpc44> NVLlN2RyOjR4NUS2NFY>
HL-60 MUDGeY5kfGmxbjDBd5NigQ>? MUCwMlHDqM7:TR?= M4jHeVczKGh? MWDicI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= MW[yOFYxPzJ5Mx?=
HepG2  NITqUJVHfW6ldHnvckBCe3OjeR?= MlHzNlAxKG6P NFj5O28xNjViaB?= M{P6e4F1fGWwdXH0[ZMhTm:6TzDwbI9{eGixconsZZRqd25? M4fV[|I1PTN3MUmy
H520 NWSwV5lPTnWwY4Tpc44hSXO|YYm= M4DsSlExyqEQvF2= NWHUZ2xOOSCq NXvBNYxOTE2VTx?= MkXI[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NXf6SVlxOjR2NEe5N|U>
H1975 MmDjSpVv[3Srb36gRZN{[Xl? MlLINVDDqM7:TR?= MkXjNUBp MVLEUXNQ NXzmPFVX\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ MV6yOFQ1Pzl|NR?=
MG-63 MofiRZBweHSxc3nzJGF{e2G7 MlzUNVAhyrWP MlixNVIhcA>? NUT1c2xl\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NFWxc4ozPDN3OEOwNS=>
5637 NES3PYZCeG:ydH;zbZMhSXO|YYm= MVmxNOKh|ryP MX:0NEBucW5? NV\PRVk5emW4ZYLz[ZMheDJzV1HGNUBmgHC{ZYPzbY9vNCCFRFug[ZhxemW|c3nvckwh[W6mIHPlcIwhcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IH\1Z49q\GGw MmC0NlQ{OzN6Nki=
HEK-293 MlOxSpVv[3Srb36gRZN{[Xl? NHqz[HMyPTCwTR?= MU[xOkBp NU\Te4pjTE2VTx?= M3vaOoRm[3KnYYPld{BEWlRiYXP0bZZqfHl? MW[yOFMzPDN4Nh?=
SW480  NWnER2lqTnWwY4Tpc44hSXO|YYm= M3zh[FE2OG6P M{fRSVIxKGh? MnPKSG1UVw>? MUfy[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw NGXiS2szPDN{NEO2Oi=>
HepG2 MW\GeY5kfGmxbjDBd5NigQ>? MYmxNFAhdk1? MlPnNlQhcA>? NVWxdmZr[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NH3NWXMzPDJ7N{WxNC=>
HCT 116  MWPGeY5kfGmxbjDBd5NigQ>? Ml;iNVAxKG6P MlXVNlQhcA>? MnfkZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? MlvBNlQzQTd3MUC=
BEL/FU M1y5VmZ2dmO2aX;uJGF{e2G7 M3;R[lEhdU1? NWXWdnppOjRiaB?= M4XI[IRm[3KnYYPld{Bxem:2ZXnuJIxmfmWuczDv[kB1cGViUFmzT{9Cc3RicHH0bJdigQ>? NEnueXkzPDJ|MkC5PS=>
Huh7  MYLGeY5kfGmxbjDBd5NigQ>? MYqzxsDPxE1? NWrIeHZDOSCq MVTy[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> M4rpZlI1OTh2MUm2
A-375 MmPMRZBweHSxc3nzJGF{e2G7 NGDqOYU1NzhizszN NXvybXQyOjRiaB?= M{XwOIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= Mne0NlQyOTNzN{O=
A-375-TS  NWXG[GI1SXCxcITvd4l{KEG|c3H5 MlXROE85KM7:TR?= MmjqNlQhcA>? Ml;U[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= Ml7wNlQyOTNzN{O=
Mel-HO MoP4RZBweHSxc3nzJGF{e2G7 NFvBZ3E1NzhizszN NYPkbYo{OjRiaB?= NEjZXHBmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg Mn\SNlQyOTNzN{O=
Mel-HO-TS MlLyRZBweHSxc3nzJGF{e2G7 NYG1O2NZPC96IN88US=> M3XoT|I1KGh? NYnXPY9X\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NIe0ZWEzPDFzM{G3Ny=>
MeWo M3;zeWFxd3C2b4Ppd{BCe3OjeR?= NEfFU5U1NzhizszN M{i0O|I1KGh? NH\xN|hmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MnLsNlQyOTNzN{O=
Mel-2a NXiwdm1bSXCxcITvd4l{KEG|c3H5 MXy0M|gh|ryP NWLqenp1OjRiaB?= NYXYWWhs\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M3nhVFI1OTF|MUez
MDA-MB-231 MXjGeY5kfGmxbjDBd5NigQ>? MV:w5qCUPDByIH7N MWC0JIg> Mo\Id5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVvueIdFOjJ7ME[yOVk>
MDA-MB-231 NIraSHdHfW6ldHnvckBCe3OjeR?= MkThOFAxKG6P NIPuXWQ1KGh? MYLk[YNz\WG|ZYOgUW1RNTliYX7kJGlNNThicILveIVqdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHINlI6ODZ{NUm=
Jurkat MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfTNE4zPS1zLkK1JO69VQ>? NWjKOIk1OjRxNEigbC=> NVSyO4RITE2VTx?= MYLpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M4nZc|E6PzV5MUi1
Namalwa NUfEVpdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rLelAvOjVvMT6yOUDPxE1? NVXQeo9QOjRxNEigbC=> MXvEUXNQ NUC4UodxcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NGXZOVgyQTd3N{G4OS=>
Jurkat NV;4bYZHSXCxcITvd4l{KEG|c3H5 NWDxfFFHOC5{NT2xMlI2KM7:TR?= MVyyOE81QCCq M4HlWGROW09? MoPtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NH[5VmsyQTd3N{G4OS=>
Namalwa M1[1VmFxd3C2b4Ppd{BCe3OjeR?= MkfXNE4zPS1zLkK1JO69VQ>? M{j4RVI1NzR6IHi= M3rxUGROW09? M3faeYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> Mm\kNVk4PTdzOEW=
K562 NUXhXJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXzS|hLOjRiaB?= MkXUTWM2OD1{NdMxNE4yPCCwTR?= NUi3[Gx1OTl4NkKzOlE>
SW1990 MmjiSpVv[3Srb36gRZN{[Xl? NFHiTnkxNjBzLUGg{txO NUDyOWFuOSCq MUjpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> M{PoR|E6PDZ7MEKw
RT112  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe5RlAyOMLizszN NX;DPIZ[OjRiaB?= NFjBSJhFVVOR NEXVSldl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? NXTCW4hFOTh5OEe4N|I>
MHG-U1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfmTlFNOTEEoN88US=> M4[yclI1KGh? M1fxXGROW09? M1TkboRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MV6xPFc5Pzh|Mh?=
SMMC-7721 MkH0RZBweHSxc3nzJGF{e2G7 NEHTZpMzODEEoH7N MWiyOEBp M1f4TIlv[3KnYYPld{BEUFhvaX7keYNm\CCjcH;weI9{cXN? NHHkXokyPzV3N{G5NS=>
SMMC-7721 MVHGeY5kfGmxbjDBd5NigQ>? NH\SSJYzODEEoH7N Mk\yNlQhcA>? M{LsNJVxNXKnZ4XsZZRmeyEQskGsOGdVOSCneIDy[ZN{cW:w M17C[FE4PTV5MUmx
HeLa NIT1PWlHfW6ldHnvckBCe3OjeR?= MWGxNFDDqG6PwrC= NV3NUHFqOSCq MWDhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= M4DvPVE3QDlyOUG1
MRC5VI NYfwVFRLTnWwY4Tpc44hSXO|YYm= M4e2PVEzNjVibV2= NELTdoMxNjViaB?= NV;NclRnTE2VTx?= MnzrZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MnLGNVYzOjd|OUS=
AT5BIVA NWHCTotITnWwY4Tpc44hSXO|YYm= MlzBNVIvPSCvTR?= Mn76NE42KGh? MkHWSG1UVw>? MlfWZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MWKxOlIzPzN7NB?=
M059J M{fNeWZ2dmO2aX;uJGF{e2G7 MlvNNVIvPSCvTR?= MkPSNE42KGh? MV;EUXNQ M1zR[4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh Ml;WNVYzOjd|OUS=
HeLa Ml3KSpVv[3Srb36gRZN{[Xl? MWexNk42KG2P NFnJfJQxNjViaB?= NWf2[HhbTE2VTx?= NXu5OYZV[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MUWxOlIzPzN7NB?=
N2a NWr0d4YySXCxcITvd4l{KEG|c3H5 NIrnR4UxNjFvMUCg{txO NXvENGJUOiCq MlnvbY5lfWOnczDk[YNz\WG|ZXSgZ4VtdCC4aXHibYxqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MofSNVU5PDJ5Nke=
Jurkat  NF;4c|NMcW6jc3WgRZN{[Xl? M1raSmlEPTBib3[gNlQhdk1? NGLCO4MyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID